Amgen Inc.’s experimental heart drug, designed to imitate the cholesterol-lowering effects of a rare genetic mutation, cut levels of the blood fat by 55 percent to 66 percent in clinical trials.
Sitting in Memorial Hall at the heart of the Chapel Hill campus of the University of North Carolina, Mary Willingham wondered what William Friday would want her to do.
Amgen Inc. won expanded U.S. approval for its drug Vectibix as an initial treatment in patients with a type of advanced colorectal cancer who first undergo genetic screening.
IPayment Inc.’s debt rating was cut by Moody’s Investors Service on an “elevated risk of default” after the credit-card processor reported losses and fewer merchants using the service.
Amgen Inc., the world’s largest biotechnology company by revenue, disappointed analysts with lower-than-estimated sales of its top drug, sending shares down the most in a year.